ImmunityBio, Inc. — Cash Flow Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Capital Allocation
How management deploys cash: investing in the business (Capex + M&A) vs returning to shareholders (Buybacks + Dividends).
Capital Allocation Waterfall
Buybacks vs Stock-Based Comp
Cash Flow
Cash Flow by Activity
Operating Cash Flow↑+19.7% +$21M
$-86M
Free Cash Flow↑+57.2% +$1M
$-903K
Investing Cash Flow↑+343.1% +$34M
$44M
Financing Cash Flow↓-48.7% -$52M
$55M
Capex↓-57.2% -$1M
$903K
Acquisitions
—
Stock Buybacks
—
Stock-Based Comp↓-3.2% -$292K
$9M
D&A↓-6.6% -$273K
$4M
SBC Allocated Expense↓-3.2% -$292K
$9M